Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Nephrostomy, Percutaneous | 4 | 2011 | 11 | 0.590 |
Why?
|
| Kidney Calculi | 2 | 2013 | 44 | 0.450 |
Why?
|
| Microscopy, Acoustic | 1 | 2013 | 10 | 0.390 |
Why?
|
| Lithotripsy | 1 | 2013 | 53 | 0.370 |
Why?
|
| Radiation Dosage | 2 | 2010 | 196 | 0.350 |
Why?
|
| Erectile Dysfunction | 2 | 2008 | 38 | 0.340 |
Why?
|
| Urolithiasis | 1 | 2010 | 11 | 0.310 |
Why?
|
| Penile Prosthesis | 1 | 2008 | 3 | 0.280 |
Why?
|
| Urinary Sphincter, Artificial | 1 | 2008 | 7 | 0.280 |
Why?
|
| Urinary Incontinence | 1 | 2008 | 65 | 0.260 |
Why?
|
| Patient Satisfaction | 1 | 2008 | 710 | 0.200 |
Why?
|
| Sus scrofa | 2 | 2013 | 64 | 0.180 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2011 | 140 | 0.170 |
Why?
|
| Cardiology | 1 | 2023 | 365 | 0.160 |
Why?
|
| Acute Coronary Syndrome | 1 | 2023 | 297 | 0.150 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2023 | 265 | 0.150 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2010 | 2772 | 0.150 |
Why?
|
| Dietary Supplements | 2 | 2023 | 580 | 0.140 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2023 | 559 | 0.130 |
Why?
|
| Androgen Antagonists | 2 | 2008 | 92 | 0.130 |
Why?
|
| Carotid Artery Diseases | 1 | 2016 | 70 | 0.120 |
Why?
|
| Biological Products | 1 | 2019 | 258 | 0.110 |
Why?
|
| Urography | 2 | 2011 | 19 | 0.110 |
Why?
|
| Equipment Safety | 1 | 2013 | 38 | 0.100 |
Why?
|
| Electromagnetic Fields | 1 | 2013 | 37 | 0.100 |
Why?
|
| Vesico-Ureteral Reflux | 1 | 2012 | 38 | 0.090 |
Why?
|
| Myocardial Infarction | 1 | 2020 | 1216 | 0.090 |
Why?
|
| Dextrans | 1 | 2012 | 87 | 0.090 |
Why?
|
| Ureteral Obstruction | 1 | 2012 | 63 | 0.090 |
Why?
|
| Ureteroscopes | 1 | 2011 | 4 | 0.080 |
Why?
|
| Optical Phenomena | 1 | 2011 | 9 | 0.080 |
Why?
|
| Nephrons | 1 | 2011 | 23 | 0.080 |
Why?
|
| Equipment Design | 1 | 2013 | 532 | 0.080 |
Why?
|
| Air | 1 | 2011 | 45 | 0.080 |
Why?
|
| Prostatic Neoplasms | 2 | 2008 | 978 | 0.080 |
Why?
|
| Organ Specificity | 1 | 2011 | 312 | 0.080 |
Why?
|
| Hemostatics | 1 | 2011 | 63 | 0.080 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2011 | 69 | 0.080 |
Why?
|
| Hyaluronic Acid | 1 | 2012 | 225 | 0.080 |
Why?
|
| Cardiovascular Diseases | 1 | 2023 | 2185 | 0.080 |
Why?
|
| Fluoroscopy | 1 | 2011 | 181 | 0.080 |
Why?
|
| Swine | 1 | 2013 | 833 | 0.080 |
Why?
|
| Awards and Prizes | 1 | 2011 | 72 | 0.080 |
Why?
|
| Models, Animal | 1 | 2011 | 395 | 0.070 |
Why?
|
| Canada | 2 | 2023 | 434 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2023 | 2582 | 0.070 |
Why?
|
| Endoscopy | 1 | 2011 | 317 | 0.070 |
Why?
|
| Libido | 1 | 2008 | 24 | 0.070 |
Why?
|
| Urologic Surgical Procedures, Male | 1 | 2008 | 32 | 0.070 |
Why?
|
| Sensitivity and Specificity | 1 | 2013 | 2002 | 0.070 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2008 | 72 | 0.070 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2011 | 260 | 0.070 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2008 | 192 | 0.060 |
Why?
|
| Blood Glucose | 1 | 2016 | 2330 | 0.060 |
Why?
|
| Prosthesis Design | 1 | 2008 | 360 | 0.060 |
Why?
|
| Insulin | 1 | 2016 | 2506 | 0.060 |
Why?
|
| Humans | 14 | 2023 | 145491 | 0.050 |
Why?
|
| Dementia | 1 | 2008 | 325 | 0.050 |
Why?
|
| Kidney | 1 | 2011 | 1498 | 0.050 |
Why?
|
| Middle Aged | 7 | 2020 | 36176 | 0.050 |
Why?
|
| Aged, 80 and over | 5 | 2020 | 8326 | 0.050 |
Why?
|
| Male | 9 | 2020 | 72817 | 0.050 |
Why?
|
| Disease Models, Animal | 1 | 2013 | 4559 | 0.050 |
Why?
|
| Aged | 6 | 2020 | 26125 | 0.040 |
Why?
|
| Female | 7 | 2020 | 78763 | 0.040 |
Why?
|
| Anxiety | 1 | 2008 | 1127 | 0.040 |
Why?
|
| Liver Cirrhosis | 1 | 2023 | 287 | 0.040 |
Why?
|
| Risk Factors | 2 | 2016 | 10874 | 0.040 |
Why?
|
| Prognosis | 2 | 2020 | 4323 | 0.040 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2023 | 505 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2020 | 3759 | 0.040 |
Why?
|
| Adult | 6 | 2023 | 40707 | 0.040 |
Why?
|
| Depression | 1 | 2008 | 1573 | 0.030 |
Why?
|
| Logistic Models | 2 | 2016 | 2130 | 0.030 |
Why?
|
| Lipids | 1 | 2023 | 709 | 0.030 |
Why?
|
| Musculoskeletal Diseases | 1 | 2019 | 90 | 0.030 |
Why?
|
| Retrospective Studies | 3 | 2010 | 17269 | 0.030 |
Why?
|
| Carotid Intima-Media Thickness | 1 | 2016 | 75 | 0.030 |
Why?
|
| Asymptomatic Diseases | 1 | 2016 | 103 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2011 | 1544 | 0.030 |
Why?
|
| China | 1 | 2016 | 271 | 0.030 |
Why?
|
| Models, Statistical | 1 | 2020 | 679 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2016 | 529 | 0.030 |
Why?
|
| Linear Models | 1 | 2016 | 848 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2016 | 1082 | 0.030 |
Why?
|
| Time Factors | 2 | 2016 | 7171 | 0.020 |
Why?
|
| Coronary Artery Disease | 1 | 2020 | 760 | 0.020 |
Why?
|
| Animals | 2 | 2013 | 38141 | 0.020 |
Why?
|
| Ureteroscopy | 1 | 2012 | 15 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 1755 | 0.020 |
Why?
|
| Fibrin Tissue Adhesive | 1 | 2011 | 20 | 0.020 |
Why?
|
| Intraoperative Care | 1 | 2011 | 63 | 0.020 |
Why?
|
| Pliability | 1 | 2011 | 48 | 0.020 |
Why?
|
| Anthropometry | 1 | 2011 | 205 | 0.020 |
Why?
|
| Color | 1 | 2011 | 81 | 0.020 |
Why?
|
| Phantoms, Imaging | 1 | 2011 | 159 | 0.020 |
Why?
|
| Nephrectomy | 1 | 2011 | 161 | 0.020 |
Why?
|
| Postoperative Care | 1 | 2011 | 286 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2011 | 771 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 2950 | 0.020 |
Why?
|
| Disease Progression | 1 | 2016 | 2862 | 0.020 |
Why?
|
| Orchiectomy | 1 | 2008 | 73 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2023 | 11831 | 0.020 |
Why?
|
| Penile Erection | 1 | 2008 | 7 | 0.020 |
Why?
|
| Contrast Media | 1 | 2011 | 500 | 0.020 |
Why?
|
| Recurrence | 1 | 2011 | 1142 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2011 | 1332 | 0.020 |
Why?
|
| Androgens | 1 | 2008 | 178 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2008 | 1001 | 0.010 |
Why?
|
| Biomarkers | 1 | 2016 | 4283 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2008 | 1304 | 0.010 |
Why?
|
| Length of Stay | 1 | 2011 | 1348 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2011 | 3424 | 0.010 |
Why?
|
| Child | 1 | 2023 | 22680 | 0.010 |
Why?
|
| Mental Health | 1 | 2008 | 795 | 0.010 |
Why?
|
| Infant | 1 | 2012 | 10064 | 0.010 |
Why?
|
| Young Adult | 1 | 2011 | 14192 | 0.010 |
Why?
|
| Adolescent | 1 | 2011 | 22485 | 0.010 |
Why?
|